Alzheimer's disease as oligomeropathy
Neurochemistry International, ISSN: 0197-0186, Vol: 119, Page: 57-70
2018
- 98Citations
- 115Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations98
- Citation Indexes98
- 98
- CrossRef87
- Captures115
- Readers115
- 115
- Mentions2
- News Mentions2
- News2
Most Recent News
Cerebral apolipoprotein E and amyloid precursor-like protein 1 as risk factors for chronic neurodegeneration after non-traumatic acute brain injury (ABI)
Acute brain injury (ABI) is defined as damage to the brain parenchyma as a result of an acute traumatic or non-traumatic (e.g., subarachnoid hemorrhage [SAH],
Review Description
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and is characterized by pathological aggregates of amyloid β-protein (Aβ) and tau protein. On the basis of genetic evidence, biochemical data, and animal models, Aβ has been suggested to be responsible for the pathogenesis of AD (the amyloid hypothesis). Aβ molecules tend to aggregate to form oligomers, protofibrils, and mature fibrils. Although mature fibrils in the final stage have been thought to be the cause of AD pathogenesis, recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models, and human samples, such as cerebrospinal fluids and postmortem brains of AD patients, suggest that pre-fibrillar forms (oligomers of Aβ) are more deleterious than are extracellular fibril forms. Based on this recent evidence showing that oligomers have a central role in the pathogenesis of AD, the term “oligomeropathy” could be used to define AD and other protein-misfolding diseases. In this review, I discuss recent developments in the “oligomer hypothesis” including our research findings regarding the pathogenesis of AD.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0197018617303315; http://dx.doi.org/10.1016/j.neuint.2017.08.010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85027520598&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/28821400; https://linkinghub.elsevier.com/retrieve/pii/S0197018617303315; https://dx.doi.org/10.1016/j.neuint.2017.08.010
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know